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Azar BaradaranDear Editor-in-Chief
I read with interest the published article in the
esteemed journal by Heshmat et al., entitled “effect of
vitamin D on insulin resistance and anthropometric pa-
rameters in type 2 diabetes; a randomized double-blind
clinical trial” [1]. The study has focused to investigate
the effect of injection of vitamin D on insulin resistance
and anthropometric parameters in type 2 diabetes
mellitus (T2DM) [1]. Heshmat et al. studied 42 diabetic
patients with similar baseline characteristics in two
groups; intervention group with single intramuscular in-
jection of 300,000 IU of vitamin D3 and the placebo
group. They found that, 3 months after vitamin D injec-
tion, HbA1c, anthropometric factors and homeostasis
model assessment (HOMA) index in intervention group
stayed constant, however, serum 25- OHD3 was signifi-
cantly increased. They suggested that, single injection
of vitamin D was not accompanied by better diabetes
control and improvement of insulin resistance [1].
Similar to this study, we conducted a double blind
randomized clinical trial on 60 T2DM patients who
were divided into 2 groups with 30 patients in each
[2]. Group 1 were treated with oral Vitamin D, and
group 2 were treated with placebo drug. After 3 months
of treatment intervention, no significant difference of
serum HbA1c and lipids between two groups was found.
We concluded that, weekly vitamin D supplementation
for 12 weeks had not significant decremented effect on
HbA1c and lipid profiles [2].
Studies concerning the beneficial effects of vitamin
D supplementation on improvement of diabetes or
improvement of insulin sensitivity are limited andCorrespondence: azarbaradaran@yahoo.com
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reproduction in any medium, provided the orrevealed different results. To find, whether receiving
vitamin D3 (4000 IU/d) is associated with improved
markers of insulin sensitivity and resistance, and also
reduced inflammation in obese adolescents, Belenchia
et al. studied participants who have supplemented
with vitamin D3 for 6 months. They found a signifi-
cant increase in serum 25-hydroxyvitamin D concen-
trations after this period. However, there were no
significant differences in body mass index, serum inflam-
matory markers or plasma glucose concentrations in
comparison to control group. Moreover, inflammatory
markers remained unchanged [3]. Meanwhile, in the study
conducted by Lim et al., on 1080 non-diabetic Korean
subjects, it was found that 25(OH)D baseline is associated
with the incidence of T2DM in high-risk subjects for up
to 5 years of follow-up, independently of obesity, baseline
insulin resistance, and β cell function [4]. Furthermore, to
test the association of low plasma 25-hydroxyvitamin D
with increased risk of T2DM in the general population,
Afzal et al. measured 25-hydroxyvitamin D level in 9841
participants from the general population, of whom 810 de-
veloped type 2 diabetes during 29 years of follow-up. They
found the association of low plasma 25-hydroxyvitamin
D with increased risk of T2DM [5].
Prevalence of type 2 diabetes mellitus (T2DM) is
increasing worldwide [6-11] and based on increasing
evidence from animal and human studies, vitamin D de-
ficiency is now regarded as a potential T2DM risk factor
[12-18]. Hence, the present data is not convincing and
further studies with large sample sizes are needed to
show the definite effect of vitamin D supplementation
on control of diabetes and its risk.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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